IBB holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 20 issuer countries.

IBB's largest investment is Vertex Pharmaceuticals Inc at 8.08% of net assets. Amgen Inc and Gilead Sciences Inc follow; the three together are 22.75%. Ten companies are 44.63% of the fund; the other 241 share the rest. Among the 721 equity funds measured here, IBB behaves like 34.6 holdings against a median of 42.4 — close to the median. Across 28 quarterly filings IBB has become less concentrated: it behaved like 27.6 at 2019-09-30 and 34.6 at 2026-06-30. Between the 2026-03-31 and 2026-06-30 filings 2 positions were added and 8 dropped; 11.3% of the weight moved. the United States is the largest country at 86.09% of the portfolio, across 20 countries in the filing.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2019-09-30 and 2026-06-30, IBB went from behaving like 27.6 equally weighted positions to 34.6 — 25% more, while its top ten went from 53.07% to 44.63% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

Measured against every other fund on this site, from the same filings. Combined effective holdings is how the pair behaves held in equal size.

IBB's filing lists 252 positions including 11.66% of net assets in securities-lending cash collateral. Counted as filed the fund reads 23.4 effective holdings with a top ten of 54.33%; on its own investments — the figure above — it reads 34.6 with a top ten of 44.63%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.

The 15 largest of 251 positions in IBB's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: IBB.csv.gz.

Share of IBB's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of IBB's own filings, 84 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.05 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: IBB.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-06-30, $1.1bn was out to 29 borrowers, 11.63% of net assets. The largest, JP MORGAN SECURITIES LLC, held 30.5% of it.

Cash collateral reported against the loan: 11.66% of net assets, 100.2% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter IBB has filed, with each borrower: IBB.json · all funds.

251 positions became 245: 2 added (1.3% of the fund at the later date), 8 dropped (3.2% at the earlier date). Half the sum of all weight changes, a turnover proxy: 11.3%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of IBB compared this way, as a feed: changes.xml · all funds: filings received.

New: Ascendis Pharma A/S (1.28%), Arcellx, Inc. (0.00%). Gone: Ascendis Pharma A/S (0.96%), Arcellx, Inc. (0.47%), Terns Pharmaceuticals, Inc. (0.46%), Amicus Therapeutics, Inc. (0.41%), Apellis Pharmaceuticals, Inc. (0.39%), Centessa Pharmaceuticals plc (0.25%).

89.24% equity, 10.76% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $9.09B. Notional of an interest-rate or currency swap is not equity exposure.

Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of IBB (34.6). Same filings, same arithmetic. Position in this list says nothing about which fund is better.

• XBI vs IBB: Equal-Weight vs Cap-Weight Biotech — Two Very Different Risk Profiles

  XBI weights biotech names roughly equally, tilting hard toward small- and mid-cap clinical-stage companies; IBB is cap-weighted and dominated by a handful...

  10 Aug 2026 9 min ETF Analysis